Cytomegalovirus Hepatitis in Immunocompetent and Immunocompromised Hosts

Teresa Da Cunha*1 and George Y. Wu1,2

1Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA; 2Current address: Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA

Abstract

Human cytomegalovirus (HCMV) infection is common and affects between 40–100% of the worldwide population. However, the majority of cases are asymptomatic and when severe disease occurs, it is usually restricted to immunocompromised patients. Liver involvement by HCMV differs significantly, accordingly to the immune status of the host. In immunocompromised patients, particularly liver transplant patients, it often causes clinically significant hepatitis. On the other hand, in immunocompetent patients, HCMV hepatitis requiring hospitalization is extremely rare. This review aims to appraise studies regarding the pathophysiology of HCMV hepatitis, including mechanisms of latency and reactivation and its contribution to disease development, clinical presentation, diagnostic modalities and treatment, with a focus on comparing different aspects between immunocompromised and immunocompetent hosts.

Citation of this article: Da Cunha T, Wu GY. Cytomegalovirus hepatitis in immunocompetent and immunocompromised hosts. J Clin Transl Hepatol 2021;000(000):000–000. doi: 10.14218/JCTH.2020.00088.

Introduction

Human cytomegalovirus (HCMV) is a common pathogen, thought to affect 40% to 100% of the world population.1 It is mainly transmitted through close contact by body fluids, such as saliva, blood, urine, breast milk, semen and cervical secretions, and also by organ transplantation. It can infect a vast number of cells within the host, including epithelial cells, endothelial cells, parenchymal cells, connective tissue cells and several types of hematopoietic cells. This facilitates both inter-host transmission and systemic transmission within the host.2

The clinical manifestations are extensive and vary particularly between immunocompetent and immunocompromised hosts. While the vast majority of immunocompetent hosts have a completely asymptomatic course, the immunocompromised host may experience a wide range of severe complications, including esophagitis, colitis, hepatitis, encephalitis, pneumonitis, bacterial superinfection.3 In addition, acute infection, chronic infection and reactivation of the virus generate different clinical identities.

In immunocompetent hosts, clinically significant hepatitis is rare and only case reports or small case series are available in the literature. Its presentation is usually a spectrum of malaise and fever, without the classical jaundice seen with the common hepatitis viruses.3 Other cases have reported an asymptomatic course or association with abdominal pain only. However, hepatitis is a well-known manifestation of HCMV infection in immunocompromised hosts, particularly in liver transplant patients, in which the incidence is relatively high. Indeed, fulminant hepatitis requiring living-donor liver transplant has been described in this population.4

Like other herpes viruses, HCMV has the ability to create a lifelong latent infection. Through a variety of complex mechanisms, HCMV modulates the host cell cycle to create an optimal environment for continuous and efficient replication.5 This lifecycle characteristic allows for viral reactivation and consequently HCMV-related acute disease, including acute hepatitis.

The exact mechanisms by which HCMV induces hepatitis are not well established. However, the role of the immune system appears to be important as an indirect cause of liver damage. Because of the overall rarity of the disease, especially in immunocompetent patients, delay in diagnosis is common, resulting in unnecessary and expensive diagnostic testing. Furthermore, delays can lead to incorrect management and poor outcomes.

The aim of this manuscript is to review the pathogenesis, presentation, diagnosis and management of HCMV hepatitis, with a focus on host immune status.

Epidemiology

The overall seroprevalence of HCMV has been estimated to range from 45% to 100%.1 This large number is related to the high number of asymptomatic individuals who do not seek medical care. In addition, several risk factors contribute to changes in seropositivity rate across various groups. According to the National Health and Nutrition Examination Surveys from 1988–2004, which analyzed the HCMV seroprevalence in the USA, HCMV prevalence was associated with increasing age and was slightly higher in women, non-Hispanic black ethnicity, and Mexican Americans. Furthermore, foreign birthplace, lack of insurance, and low income and low education households were also associated with a higher infection rates.6

Symptomatic HCMV infection is rare in immunocompe-
When present, it usually manifests as a mononucleosis-like syndrome in approximately 10% of patients. The estimated incidence of mononucleosis-like syndrome secondary to HCMV infection in hospitalized immunocompetent patients in Hong Kong was reported to be 9.54 per million patient discharges in 2005–2007, and 19.52 per million patient discharges for the period of 2014–2016.

Even though liver dysfunction is not uncommonly associated with HCMV mononucleosis in immunocompetent hosts, there are only case reports of clinically significant HCMV hepatitis available in the literature. To date, there have been 26 descriptions of either case reports or case series of HCMV hepatitis in a total of 44 immunocompetent hosts.

On the other hand, clinically significant HCMV hepatitis is more frequent in the immunocompromised population, particularly in liver transplant patients. For instance, Seehofer et al. observed a 2.1% rate of HCMV hepatitis in 1,146 consecutive liver transplantations. In terms of incidence of viremia, in a study of 182 liver transplant patients to whom pre-emptive therapy was used but no antiviral prophylaxis was employed, Singh et al. observed a HCMV infection rate of 32.5% (68 of 117) among patients who were positive for donor (D+)/recipient negative (R−), 84.6% (33 of 39) of donor positive (D+)/recipient negative (R−), and 3.8% (1 of 26) of donor negative (D−)/R− patients.

Pathogenesis of HCMV

Systemic viral dissemination

The HCMV possesses glycoproteins that can interact with a vast number of different cell surfaces within the human body and initiate its life cycle. This unique characteristic allows for a broad cellular tropism. The hematogenous spread of the virus allows for its systemic dissemination. Recent observations have shown that polymorphonuclear leukocytes can more efficiently carry and disseminate the virus. Nonetheless, Sinzger et al. also observed infected macrophages in the lung and gastrointestinal tissues. Later studies supported this by suggesting that monocytes carry a comparable amount of viral load, thus contributing to systemic viral dissemination. Once successful termination of acute infection is achieved, a period of latency/per sistence is initiated, during which multiple episodes of viral reactivation and transmission can occur.

HCMV infection of hepatic cells

Theise et al. studied liver biopsies from seven patients with HCMV hepatitis and detected that the infection started in the cells lining the sinusoids (including Kupffer and endothelial cells), proposing that hematogenous spread to the liver occurs first. Furthermore, hepatocytes were noted to be infrequently infected. On the contrary, Sano et al. found that hepatocytes were the most frequently infected cell line, and bile duct involvement was only identified in one case. However, they did not provide evidence of infection in Kupffer cells or other sinusoidal cells. Sinzger et al. studied HCMV infection in cultured human liver cells. They detected viral antigens from all phases of viral replication, suggesting that the tissue allowed for complete viral replication. In this study, various target cells were identified by immunocytochemical double-labeling, including bile duct cells, fibroblasts, and hepatocytes. They observed that hepatocytes were the primary cell target and supported the late stages of viral replication, indicating that this cell line participates in production of progeny virus. Olver et al. also found that hepatocytes were the predominant cell target in HCMV hepatitis in their mice studies.

Indirect vs. direct cytopathogenicity of HCMV in the liver

It has been reported that the HCMV exhibits both direct and indirect cytopathogenicity in various organs, including the liver. It is believed that liver dysfunction occurs primarily from indirect cytopathogenicity of cytotoxic T-lymphocyte (CD8+) lineage. Pape et al. identified accumulations of cytolytic T lymphocytes in the areas of liver tissue injury caused by HCMV, by means of monoclonal antibodies. This provided evidence of indirect pathogenicity by immune-related cytotoxicity and cytokine damage from the host immune system defense against the virus. Several hypotheses have emerged to explain the mechanism of tissue damage through indirect cytopathogenicity, including activation of cytotoxic T cell reactions against HCMV-infected cells, vasculitic alterations and subsequent localized necrosis, and in relation to allograft transplantation. In the latter, the proposed mechanism comprises a possible enhancement in the frequency of lymphocytic activation or increased MHC expression, which further exacerbated the immunological detrimental effects. Sinzger et al. observed lysis of cultured liver cells infected with HCMV, supporting the role of the virus in direct cytopathogenicity. They concluded that HCMV can cause direct liver parenchyma damage through cytopathic mechanisms. However, despite the fact that the virus can be present in hepatocytes and bile ducts, its presence in the majority of cases has been shown to be moderate and not correlated to the degree of liver dysfunction.

Stahli et al. demonstrated that liver damage and consequent release of liver enzymes in immunocompetent mice occurred earlier than in immunocompromised. This observation can be explained by the early immune response that mainly involves T lymphocytes and natural killer cells and contributes to early tissue damage. However, there was a decrease in liver enzymes at day 6 after infection, which reflects the host immune control over the virus. In contrast, in immunocompromised mice, the elevation of liver enzymes was observed later and lasted longer. Consequently, the liver damage in this host occurred later and was attributed to direct cytopathic effect caused by the virus.

Liver involvement by the HCMV has been reported as hepatitis alone, granulomatous hepatitis, necrotizing hepatitis, and hepatic dysfunction associated with portal vein thrombosis. As mentioned before, although direct cytopathogenicity does play a role in these identities, the inflammatory response with continuous cytokine release appears to be the predominant hepatoportal mechanism, especially in immunocompetent patients. Thus, there is an important
balance between the protective effects and extent of tissue damage caused by a natural host immune response.

**Mechanism of HCMV latency and reactivation**

**Latency**

During HCMV infection in the liver, liver sinusoidal endothelial cells (LSECs) do not function as a barrier to the virus. Rather, they allow for dissemination to the rest of the liver. Seckert and colleagues studied the function of these cells in mice when exposed to HCMV. They observed that LSECs were sites for murine HCMV latency and potential reactivation. However, the same was not observed in hepatocytes.

Other functions of LSECs have been hypothesized. Namely, their role in modulating T cell recruitment and activation, and thus in promoting immune activation in the liver. Specifically, it has been shown that these cells facilitate the transendothelial migration of ICAM-1 and CXCL10-dependent T cells. Furthermore, in that study, recruited T cells were primarily non-virus-specific effector memory T cells and activated regulatory T cells with a suppressive phenotype. Thus, this cell type contributes to viral persistence.

Hepatocytes play a major role in viral production and disease, but do not directly contribute to viral latency. On the contrary, LSECs have a very small capacity to allow viral reproduction and for this reason are less susceptible for direct viral cytopathogenicity and function as an optimal environment for viral latency.

**Reactivation**

HCMV is able to escape both innate and adaptive immunity. Several genes have the ability to down-regulate major histocompatibility complex (MHC) class I and MHC class II and may be involved in inhibition of antigen presentation.

Furthermore, HCMV can activate or down-regulate receptors found on natural killer cells, natural killer T cells, and T cells. Several factors can influence reactivation of the virus, including immune cell depletion, allogenic transplantation, ischemia/reperfusion injury, sepsis, and other inflammatory states.

Although HCMV reactivation results in systemic viremia, subsequent hepatitis as a result of viral reactivation has not been clearly reported in immunocompetent patients. However, in liver recipient patients, HCMV reactivation can cause hepatitis, but at a much lower risk compared to primary infection. From among 93 liver transplant cases, Paya et al. reported that 19 of the cases developed HCMV infection. However, from the group of HCMV-seronegative-donor/HCMV-seropositive-recipients, only one developed hepatitis. Patients undergoing liver transplant are at increased risk of HCMV reactivation, particularly if receiving antilymphocyte preparations, which are highly potent reactivators of HCMV. On the other hand, immunosuppressors such as cyclosporine and corticosteroids do not cause reactivation but can contribute to increased viral replication.

Reactivation of the virus in liver transplant can be both the cause and the consequence of allograft rejection. Razonable et al. studied the clinical predictors of late-onset HCMV disease in liver and kidney transplant recipients who received oral ganciclovir prophylaxis. They observed that allograft rejection was a significant risk factor for occurrence of HCMV disease, including hepatitis. Furthermore, its incidence was higher among liver transplant recipients. This might be explained by the release of multiple cytokines, particularly TNF-α, which has been shown to induce HCMV reactivation. On the other hand, immunosuppressive therapy inhibits viral cell-mediated immunity, allowing increased viral replication rates.

**Clinical presentation**

The clinical presentation of HCMV infection varies among immunocompetent and immunocompromised hosts, as well as between acute and chronic stages. The spectrum is wide and can range from an asymptomatic infection to life-threatening. Nonetheless, the majority of patients, both immunocompetent and immunocompromised, undergo an asymptomatic disease course from the acute phase until the persistent and latent phases. The main at-risk immunocompromised hosts are fetuses, allograft recipients (due to cytotoxic anti-rejection agents), and human immunodeficiency virus infection. In these hosts, severe end-organ dysfunction can occur, such as hepatitis, retinitis, thrombocytopenia, and neurologic disease.

**Immunocompetent patients**

Immunocompetent hosts with HCMV infection may experience a mononucleosis-like syndrome with fevers, malaise, presence of lymphocytosis with atypical lymphocytes, occasionally a rash, and abdominal pain. Furthermore, associated hepatic dysfunction and splenomegaly are common. In contrast with Epstein-Barr virus (commonly known as EBV), this presentation usually does not involve tonsillitis and cervical lymphadenopathy, and there is no detectable heterophile antibody.

Given the overall rarity, only case reports or small case series of HCMV-induced hepatitis in immunocompetent patients have been published. We found 26 studies reporting HCMV-induced hepatitis in immunocompetent hosts, comprising a total of 44 patients. A total of 34 (77%) patients either had fever at home or upon presentation or malaise (n=13) and abdominal pain (n=10). On exam, only 10 (23%) patients had jaundice. Similarly, lymphadenopathy was only present in 10 (23%) patients, while 5 (11%) patients presented with a non-specific rash. Furthermore, 22 (50%) of the patients had either splenomegaly and/or hepatomegaly. Table 1 summarizes the clinical presentation of immunocompetent patients with HCMV hepatitis.

**Immunocompromised (liver transplant patients)**

The main groups of adult immunocompromised hosts susceptible to HCMV disease include allograft recipients and patients with human immunodeficiency virus infection with loss of CD4+ lymphocytes. More recently, the use of anti-TNF therapy has also resulted in severe HCMV disease with end-organ dysfunction. Amongst the different types of immunocompromised hosts, there is a common viral syndrome with fever and malaise and possibly elevated liver enzymes. Studies on significant HCMV-induced hepatitis in the immunocompromised population have only been well described in liver transplant patients.

Liver transplant patients had a reported high incidence of HCMV infection which led to a viral syndrome with fever, malaise and some degree of bone marrow suppression, or tissue invasive disease. The latter mainly affects the gastrointestinal tract (i.e. gastritis, esophagitis, enteritis, and/or colitis) and with a relatively high incidence, the liver, and consequently hepatitis. An important aspect that is regarded as a risk factor for HCMV disease in liver transplant-
Table 1. Most common presenting signs and symptoms of HCMV hepatitis in immunocompetent patients

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Age</th>
<th>Gender, M:F</th>
<th>Fever</th>
<th>Malaise</th>
<th>Abdominal pain</th>
<th>Jaundice</th>
<th>Hepato and/or splenomegaly</th>
<th>Lymphadenopathy</th>
<th>Additional diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ates et al.⁵¹</td>
<td>1</td>
<td>28</td>
<td>1:1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>Bonkowsky et al.⁴³</td>
<td>2</td>
<td>27.5</td>
<td>2:1</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>Chan et al.⁴⁷</td>
<td>1</td>
<td>29</td>
<td>0:1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Clarke et al.⁵²</td>
<td>3</td>
<td>48</td>
<td>0:3</td>
<td>3</td>
<td>1</td>
<td>–</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>Fernandez-Ruiz et al.⁶²</td>
<td>1</td>
<td>32</td>
<td>0:1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>Groza et al.³</td>
<td>1</td>
<td>12</td>
<td>1:1</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>Prashant-Gupta et al.⁵⁴</td>
<td>1</td>
<td>20</td>
<td>1:1</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Jensen et al.⁵⁵</td>
<td>1</td>
<td>35</td>
<td>0:3</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Kanno et al.³</td>
<td>1</td>
<td>28</td>
<td>1:1</td>
<td>8</td>
<td>–</td>
<td>–</td>
<td>11</td>
<td>4</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ladd et al.⁴⁸</td>
<td>1</td>
<td>17</td>
<td>1:1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Portal vein thrombosis</td>
</tr>
<tr>
<td>Miguelez et al.⁴²</td>
<td>1</td>
<td>32</td>
<td>1:1</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Oku et al.⁵⁷</td>
<td>1</td>
<td>55</td>
<td>0:1</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>Guillain-Barré</td>
</tr>
<tr>
<td>Puccia et al.⁴⁶</td>
<td>1</td>
<td>30</td>
<td>0:1</td>
<td>1</td>
<td>–</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>Portal vein thrombosis</td>
</tr>
<tr>
<td>Qian et al.⁴⁹</td>
<td>1</td>
<td>66</td>
<td>0:1</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>Ascites and pancytopenia</td>
</tr>
<tr>
<td>Reller et al.⁴¹</td>
<td>1</td>
<td>30</td>
<td>1:1</td>
<td>1</td>
<td>–</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Sacks et al.⁴⁰</td>
<td>1</td>
<td>59</td>
<td>1:1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Serna-Higuera et al.⁵¹</td>
<td>1</td>
<td>39</td>
<td>0:1</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>Hepatic necrosis</td>
</tr>
<tr>
<td>Shusterman et al.⁴⁵</td>
<td>1</td>
<td>33</td>
<td>0:1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ten Napel et al.⁴⁴</td>
<td>6</td>
<td>46</td>
<td>2:4</td>
<td>4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Toghill et al.⁵⁸</td>
<td>2</td>
<td>40</td>
<td>2:0</td>
<td>2</td>
<td>–</td>
<td>–</td>
<td>2</td>
<td>2</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Tzavella et al.⁵⁹</td>
<td>1</td>
<td>34</td>
<td>0:1</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Hooi et al.⁵⁰</td>
<td>1</td>
<td>38</td>
<td>1:0</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Transverse myelitis</td>
</tr>
<tr>
<td>Yu et al.⁴</td>
<td>1</td>
<td>39</td>
<td>1:1</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Fulminant hepatitis</td>
</tr>
<tr>
<td>Zubiaurre et al.⁵⁰</td>
<td>1</td>
<td>36</td>
<td>0:1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Myocarditis</td>
</tr>
<tr>
<td>TOTAL, n</td>
<td>44</td>
<td>35</td>
<td>25:19</td>
<td>34</td>
<td>13</td>
<td>10</td>
<td>10</td>
<td>22</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>TOTAL, %</td>
<td></td>
<td>77</td>
<td>30</td>
<td>23</td>
<td>23</td>
<td>50</td>
<td>23</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
tion is the serological status of both the donor and recipient. HCMV-seropositive-donor/HCMV-seronegative-recipient are at increased risk of HCMV hepatitis, whereas HCMV-sero-
positive-recipients have a moderate risk and HCMV-sero-
egative-donor/HCMV-seronegative-recipient have a lower risk.30 Paya et al.30 reported an incidence of 17% of acute hepatitis following 93 liver transplantations. However, See-
hofer et al.8 evaluated 1,200 liver transplant patients and of these only 2.1% developed acute hepatitis. This difference could be due to not only the difference in sample size but also to dissimilarity in immunosuppressive therapy after trans-
plantation. For this reason, a precise number is difficult to obtain. In both studies, the incidence of acute HCMV hepatitis was higher in seronegative recipients compared to seroposi-
tive recipients. Paya et al.30 found that HCMV hepatitis was most common in liver transplantation for cholestatic disease (i.e., primary biliary cirrhosis and primary sclerosing cholan-
gitis). Unfortunately, that study did not clearly describe the number of patients for each specific etiology requiring a liver transplant. In that same study, HCMV hepatitis was more frequent in patients who required retransplantation (38%) that in those who received one hepatic allograft (12%).

As in immunocompetent patients, patients commonly had a mononucleosis-like syndrome including fever and ma-
laise.31,65,66 In both studies discussed above, fever occurred in 24% and 84% of the patients.5,30 Furthermore, Paya et al.30 described myalgia in 31% of patients. Extrahepatic involvement was somewhat infrequent in the two studies. Pneumonitis occurred in four patients (three in Paya et al.30 and one Seehofer et al.8) and generalized organ involve-
ment in one patient.

It has been noted that HLA-donor/recipient matches were significantly higher in patients that developed HCMV hep-
titis.67 Moreover, HCMV hepatitis was reactivated after trans-
plant with Crohn’s disease who was previously on mercaptopurine and switched to infliximab 1 year prior to presentation.63 This case shows that the role of TNF-α in HCMV infection is complex. As previously mentioned, it has been associ-
ated with induction of HCMV reactivation in allograft rejec-
tion.34,35,68 However, a signaling cascade is also important in inducing an antiviral state.69,70

Role of HCMV in chronic liver disease

To understand whether HCMV infection could play a role in unexplained cases of chronic liver disease, Toghill et al.71 an-
alyzed 70 patients with cirrhosis with the following diagno-
sis: alcoholic cirrhosis, cryptogenic cirrhosis, primary biliary cirrhosis, hemochromatosis, drug-induced jaundice, second-
ary biliary cirrhosis, and congenital hepatic fibrosis. They did not find any evidence for HCMV as the cause of liver disease. There was no significant difference in the antibody titers of these patients compared to that of the general population.

On the contrary, HCMV infection in post-liver transplant patients has been associated with chronic rejection.72,73 The main suggested cause of chronic rejection is the vanishing bile duct syndrome. Lautenschlager et al.74 investigated the role of HCMV in chronic rejection in 10 patients and verified that all the patients had persistence of HCMV genome in the graft. Furthermore, HCMV reactivation was associated with late acute rejections. Moreover, Favier et al.74 verified that HCMV was associated with an increased risk of liver-related death in patients with liver cirrhosis.

Although HCMV infection has not been directly seen as the cause of liver cirrhosis, there appears to be evidence in support of a higher mortality in these patients. In addition, it is an important cause of chronic liver rejection in transplant patients.

Diagnosis

The diagnosis of HCMV hepatitis requires liver tissue biopsy for confirmation of HCMV presence in the liver. The best modality for identification of viral inclusions or viral antigens is immunohistochemistry.75 However, detection of HCMV by means of acute serology or polymerase chain reaction (PCR) can provide faster results when the suspicion of HCMV-induced hepatitis is high, allowing for an earlier man-
agement plan when biopsy results are pending. In many circumstances, particularly in immunocompetent patients who present with acute elevation of liver enzymes, acute HCMV serology may be sufficient for diagnosis of HCMV-induced hepatitis when other causes have been ruled out. Furthermore, it can be used to monitor disease progression and treatment response in combination with liver function results.

Liver enzyme tests

Elevation of hepatic aminotransferases in HCMV infection is non-specific but levels are on average lower than those seen in hepatitis caused by hepatitis viruses.3 In immuno-
compromised patients, 1.3-fold elevations in mean alanine aminotransferase has been reported. Faya et al.30 observed 2–30 times higher (mean 9.3-fold above upper limits of normal) levels of gamma-glutamyltransferase and 1–10 times higher (mean 3.6) in alkaline phosphatase levels compared to aminotransferases. Furthermore, the elevation of gamma-glutamyltransferase and alkaline phosphatase may persist longer than that of alanine aminotransferase and aspartate aminotransferase.8,30 The levels of bilirubin elevation in this study were relatively low, 1–4 times higher than the normal levels.

From the analysis of independent reported cases of hepatitis due to HCMV in immunocompetent patients, the mean aspartate aminotransferase was 422 (±582), n=38, and the mean alanine aminotransferase 521 (±579), n=37. The mean total bilirubin value was 5 mg/dL (± 9), n=33. Overall, there was a higher elevation of aminotransferases in immunocompetent patients compared to immunocompro-
mised. This observation could be related to the early and robust immune response in immunocompetent patients and the consequent indirect cytopathogenicity. These immu-

nocompromised patients underwent liver transplantation and were closely monitored for HCMV hepatitis, resulting in earlier diagnosis and subsequent treatment with ganciclovir. Bilirubin elevation was minimal in both population groups.

Serology

While serology in the immunocompetent patient plays an important role in the diagnosis of HCMV hepatitis, it has a limited role in the immunocompromised because of an immune system impairment in mounting an antibody re-
response.75 However, serological testing can provide a good assessment of recipient risk prior to transplant.31,77 In immuno-
competent patients, it provides a fast, non-invasive and less expensive test when used in the context of hepatis-
tis and when other etiologies have been ruled out. However, IgM antibody assays may be falsely positive due to per-
sistence of high IgM levels long after primary infection. It can also represent viral reactivation.78 Furthermore, HCMV IgM might be falsely positive in the presence of a positive rheumatoid factor or with infection of other herpes virus.79

The sensitivity and specificity of serology have been reported between 70.7–84.4% and 99.3–100%, respec-
Another study that compared five different commercial immunoassays for the serologic diagnosis of HCMV showed significant differences in sensitivity and specificity between the different tests as well as in cross reactions with EBV-IgM and rheumatoid factor.92

**Antigenemia**

The pp65 HCMV antigenemia assay detects HCMV antigens in peripheral blood leukocytes.39,61 It has a good utility for monitoring disease progression and treatment response. However, given its limitation of detecting the virus only in leukocytes, it may not be reliable in patients with leukopenia,78 as this may contribute to false negative results. Its sensitivity and specificity have been reported as 64% and 81%, respectively.94

**Culture**

The utility of viral culture is limited because of the long time required for results.85 In 65 patients with HCMV hepatitis, Brand et al.85 were able to confirm the diagnosis in 63 patients through histology and early antigenemia, but viral culture only contributed to the management of 1 patient among 2,508 liver biopsies. A study comparing several diagnostic techniques for HCMV detection in liver transplant patients using 108 hepatic tissue specimens also showed an overall low sensitivity (52%) of cell culture for detecting the virus.96 However, the use of shell vial assay provided results within 12 h and not only had a similar specificity to traditional culture but also higher sensitivity.87

**PCR**

PCR can identify HCMV from body fluid or tissue. Furthermore, it can provide both qualitative and quantitative measurements. Quantitative PCR is generally used in immunocompromised patients to determine which patients need preemptive therapy and for monitoring disease response.76,88 Methods using real-time PCR have better precision, are easier to perform, faster and less risk of contamination compared to conventional PCR.89,90 It is a reliable, sensitive and very specific method, with sensitivities ranging from 61–92% and specificities 75–99%.91,92

**Histopathological findings**

The most consistent finding of HCMV hepatitis in liver biopsies of both immunocompetent and immunocompromised patients is a mononuclear infiltrate.3,40–43,86,93,94 However, the degree of inflammatory infiltrate differs. Immunocompromised patients have an overall low degree of inflammatory mononuclear infiltrate. For instance, Sano et al.46 studied immunocompromised patients with underlying malignancy, and from three liver biopsies with detected HCMV, there was hardly any inflammatory infiltrate around the infected cells. Similar findings were observed in two patients after renal transplantation and one patient with Hodgkin’s disease.44

Ten patients assessed by Ten Napel et al.44 showed relative similarities to inflammation and viral expression in portal and periporal regions between both immunocompetent and immunocompromised. On the other hand, the immunocompetent patients had a higher level of mononuclear infiltrate in the liver parenchyma. However, the magnitude of hepatocyte damage was lower compared to that in immunocompromised patients. Although focal necrosis is more common in the immunocompromised population, there is one isolated report of fatal hepatitis in a previously healthy patient for whom liver biopsy had showed broad bands of necrosis.45

Lautenschlager et al.79 reviewed biopsies of 26 livers from patients who had a liver transplant and subsequent HCMV liver infection. The most common observation was the presence of micro-abscesses, which have been described before.15 Another finding that has been more frequently seen in immunocompetent patients are granulomas. In addition, these are more commonly seen in HCMV hepatitis in contrast to other viral causes of hepatitis.3,41,43

The degree of the host immunodeficiency likely affects the extension of the inflammatory reaction observed in the specimens. As discussed above, lack of immune response might allow an increased direct viral cytopathogenicity, which leads to more extensive necrosis. Despite an overall low magnitude of inflammatory infiltrate observed in the liver of these patients, the presence of either HCMV inclusion bodies or the detection of HCMV antigens confirms the diagnosis. Table 2 describes, in more detail, the biopsy findings of 22 previously healthy immunocompetent patients.40–45,47,52,53,58,61 Table 3 summarizes the main biopsy findings of immunocompetent and immunocompromised patients.

**Treatment**

The recommendations for antiviral initiation in HCMV hepatitis differ according to the patient population. As a result of a high incidence of HCMV hepatitis in patients undergoing liver transplantation, the main approach of management relies on preventing disease occurrence.32 There are two approaches in prevention, prophylaxis and preemptive therapy. In prophylaxis, antivirals are started just after transplantation occurs and last for at least 3 months. In preemptive therapy, the recipients are closely monitored for the presence of HCMV replication before any symptoms occur; if HCMV replication is identified, antiviral treatment is promptly initiated.

Antiviral prophylaxis has been the preferred method for high-risk allograft recipients (D+/R−).52 Treatment is started within 10 days of transplantation, regardless of the existence of HCMV replication or not. In these patients, acyclovir, valacyclovir, intravenous ganciclovir, and valganciclovir can be used.75 In a large study from Paya et al.,95 high-risk allograft patients receiving heart, liver, kidney or pancreas received prophylaxis with either ganciclovir or valganciclovir. The efficacy and safety of these drugs were similar but the incidence of HCMV disease was slightly lower in the valganciclovir group (17.2% vs. 18.4%). In other studies, valganciclovir has demonstrated lower incidence of HCMV disease at 6- and 12-months follow-up.32,33

Preemptive therapy involves close monitoring for viral replication, followed by initiation of therapy when HCMV is detected. At this time, there is no consensus regarding the threshold of viral load and the start of therapy. A recent meta-analysis involving 2,452 liver transplant recipients demonstrated an incidence of HCMV disease of 10% in patients receiving prophylaxis versus 7% in those receiving preemptive therapy. In addition, acute cellular rejection and mortality rates were similar in both groups. Importantly, these results comprised all D/R status.96 However, Singh et al.97 performed a randomized clinical trial to compare preemptive therapy and antiviral prophylaxis in 205 HCMV-seronegative liver transplant recipients (R−) with seropositive donors (D+). In that study, the incidence of HCMV disease
Cytomegalovirus hepatitis was significantly lower with pre-emptive therapy (9%) than with anti-viral prophylaxis (19%). Opposing these results, Bodro et al. analyzed 74 D+/R– liver recipient patients. Thirty-five patients (47%) received prophylaxis, and thirty-

Table 2. Histopathologic findings of liver biopsies in immunocompetent patients

<table>
<thead>
<tr>
<th>Study</th>
<th>Liver biopsy findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bonkowsky et al.</td>
<td>Portal triads infiltrated with lymphocytes, histiocytes, plasma cells, and neutrophils. Lobules with normal architecture. Many of the portal triads were enlarged, containing a small to moderate number of lymphocytes and histiocytes. Proliferation of RE cells and infiltration of lymphocytes in the sinusoids. Few necrotic hepatocytes. Small, sharply circumscribed granulomata made of closely packed epithelioid cells and rare lymphocytes. No giant cells.</td>
</tr>
<tr>
<td>Chan et al.</td>
<td>Mild to moderate infiltrate of small lymphocytes in the sinusoids and a beaded sinusoidal infiltrate characteristic of HCMV infection.</td>
</tr>
<tr>
<td>Clarke et al.</td>
<td>Focal areas of necrosis and many noncaseating epithelioid granulomas and portal triaditis. Non-caseating epithelioid granulomas, focal liver cell necrosis, portal triaditis. Prominent sinusoidal lymphocytic infiltrate and early granuloma formation.</td>
</tr>
<tr>
<td>Groza et al.</td>
<td>Viral hepatitis in an advanced phase.</td>
</tr>
<tr>
<td>Miguelez et al.</td>
<td>Intense mononuclear portal infiltration and severe alteration of zone 3 with confluent necrosis.</td>
</tr>
<tr>
<td>Reller et al.</td>
<td>Non-specific resolving hepatitis with sparse cellular necrosis and mononuclear infiltrates in portal areas. Scattered granulomas with giant cell formation.</td>
</tr>
<tr>
<td>Sacks et al.</td>
<td>Acute hepatitis with focal parenchymal necrosis, periportal and sinusoidal mononuclear infiltration. Focal fatty degenerative changes.</td>
</tr>
<tr>
<td>Shusterman et al.</td>
<td>Hepatic lobules markedly disrupted by broad bands of necrosis.</td>
</tr>
<tr>
<td>Toghill et al.</td>
<td>Areas of liver cell necrosis and mononuclear cell infiltration, acidophil bodies, slight portal enlargement, siderosis. Portal and periportal infiltration with chronic inflammatory cells, piecemeal necrosis, fibrosis of portal areas extending to lobules.</td>
</tr>
</tbody>
</table>

Table 3. Summary of the main histological findings of liver biopsies in immunocompetent and immunocompromised patients

<table>
<thead>
<tr>
<th></th>
<th>Immunocompetent</th>
<th>Immunocompromised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Portal tracts</td>
<td>Enlarged portal tracts</td>
<td>Mild to low mononuclear portal infiltrate</td>
</tr>
<tr>
<td></td>
<td>Prominent mononuclear portal and peri-portal infiltrate (frequent)</td>
<td>Reported inflammatory cells: mainly lymphocytes</td>
</tr>
<tr>
<td></td>
<td>Reported inflammatory cells: lymphocytes, histiocytes, plasma cells, neutrophils</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fibrosis of portal areas (rare)</td>
<td></td>
</tr>
<tr>
<td>Parenchyma</td>
<td>Giant cell granulomas (frequent)</td>
<td>Micro-abscesses (frequent)</td>
</tr>
<tr>
<td></td>
<td>Lymphocytes, monocytes</td>
<td>Giant cell granulomas (very rare)</td>
</tr>
<tr>
<td></td>
<td>Sinusoidal lymphocytic infiltrate (frequent)</td>
<td>Parenchymal and sinusoidal inflammatory reaction</td>
</tr>
<tr>
<td></td>
<td>Few necrotic hepatocytes</td>
<td>Extensive focal liver necrosis</td>
</tr>
<tr>
<td></td>
<td>Focal areas of necrosis (rare)</td>
<td></td>
</tr>
<tr>
<td>Presence of viral inclusion bodies</td>
<td>Extremely rare</td>
<td>Moderate (in inflammatory cells of portal mononuclear infiltrate and in hepatocytes)</td>
</tr>
</tbody>
</table>

Journal of Clinical and Translational Hepatology 2021 vol. 000 | 000–000 7
nine patients (53%) followed a pre-emptive strategy based on CMV antigenemia. They observed an increased rate of HCMV disease in the group that received pre-emptive therapy (33.3%) compared to the group that received prophylaxis (8.6%). Nonetheless, late-onset HCMV disease was only found in patients receiving prophylaxis (5.7%).

Another study from Weigand et al., analyzed 211 liver recipients for the occurrence of CMV infection. From these, 51.7% received prophylaxis with ganciclovir or valganciclovir of whom 84% had CMV infection despite antiviral prophylaxis. It is important to note that antiviral prophylaxis was started in cases of high-risk donor-recipient status, retransplantation, and according to clinical decision. In addition, the authors did not mention if CMV disease occurred.

If HCMV disease (including end-organ damage such as HCMV hepatitis) develops in immunocompromised patients, the main treatment is intravenous ganciclovir or valganciclovir. In addition, immunosuppressive regimens should be reduced as much as possible. The length of treatment varies according to individual response, which can be monitored by clinical and laboratory data.

Importantly, infections by ganciclovir-resistant HCMV has been rising, particularly in patients receiving pre-emptive therapy. In a study with 561 patients who underwent 616 hematopoietic stem cell transplantations (HSCTs), drug resistance was solely observed in haploidentical (haplo)-HSCT recipients receiving pre-emptive therapy and was as high as 14.3%. In such patients, treatment is challenging and depends on several factors, including which mutation has led to the viral resistance. Foscarnet is currently recommended as the first-line option, followed by cidofovir. Of note, both of these drugs have a certain degree of ganciclovir cross-resistance, particularly the latter.

The majority of immunocompetent patients with symptomatic HCMV infection had spontaneous resolution of both symptoms and laboratory abnormalities (elevated aminotransferases). For this reason, there are no specific guidelines for treatment. Furthermore, there are no major studies on antiviral therapy in immunocompetent patients with HCMV disease. Among the 45 immunocompetent patients with HCMV hepatitis that we found in the literature, management with antiviral therapy varied. Only nine cases reported the use of antiviral medications. From these, five received ganciclovir only, two received valganciclovir only, one received ganciclovir followed by foscarnet, and one received ganciclovir followed by cidofovir. Except for one case, all other cases that received antiviral therapy comprised patients with additional organ involvement or clinical deterioration; these included pancreatitis, myocarditis, acute pulmonary embolism, encephalopathy, transverse myelitis, pancytopenia, and fulminant hepatitis. Overall, from among all of the 45 five reported patients with HCMV hepatitis, only 1 died. In this patient, unfortunately, the diagnosis was made just prior to his death and many days after his admission.

Despite the fact that there is no clear indication for treatment of symptomatic HCMV infection in these populations, treatment should be considered when the liver function or overall clinical status of the patient is not improving, or if there is another organ involvement which can be an indicator of disease severity.

**Conclusions and recommendations**

Although slightly elevated aminotransferases in the setting of HCMV mononucleosis are common in immunocompetent patients, clinically significant HCMV hepatitis is uncommon, with only few cases reported. In the immunocompromised population, liver transplant patients have an increased risk of HCMV hepatitis.

Hepatocytes play a major role in HCMV replication but do not contribute to viral latency. On the contrary, LSECs have a very low capacity for viral reproduction, and for this reason are less susceptible for direct viral cytopathogenicity and function as an environment for viral latency.

Indirect cytopathogenicity, due to the host immune response, plays a major role in early liver damage, particularly in immunocompetent patients. Furthermore, in this population, hepatitis typically occurs earlier than in immunocompromised patients but also subsides earlier. This is due to the robust immune activation of immunocompetent patients. However, the poor immune response in the immunocompromised patients can lead to a prolonged state of direct cytopathogenicity and, consequently, marked detrimental effects to the liver. Hepatitis as a result of HCMV reactivation has not been reported in immunocompetent patients. In addition, in liver recipient patients, HCMV reactivation can cause hepatitis but at a much lower risk compared to primary infection.

The clinical presentation is non-specific with fever, malaise and myalgias being the most common signs/symptoms regardless of immune status. Treatment of HCMV hepatitis with antiviral therapy in the immunocompetent population is not generally recommended but should be considered in patients with severe disease and/or extra-hepatic manifestations. On the other hand, the management approach in immunocompromised patients relies on disease prevention.

**Acknowledgments**

The support of the Herman Lopata Chair in Hepatitis Research is gratefully acknowledged.

**Funding**

None to declare.

**Conflict of interest**

The authors have no conflict of interests related to this publication.

**Author contributions**

Wrote and revised the review article (TD), edited the review article (GYW).

**References**


[9] Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Among cytomegalovirus-seropositive liver transplant recipients is at risk for cyto-


[11] Jean BelTRAN PM, Cristea IM. The life cycle and pathogenesis of human cyto-


megalovirus infection in an immunocompetent adult. J Ultrason 2017;20:161–


